Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN   US0153511094

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2014 11/21/2014 11/24/2014 11/25/2014 11/26/2014 Date
192.55(c) 191.02(c) 194.15(c) 192.77(c) 194.72(c) Last
554 249 1 086 558 810 271 659 807 704 468 Volume
+0.31% -0.79% +1.64% -0.71% +1.01% Change
More quotes
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders.It focuses on developing products for the treatment of diseases in the... 
Sector
Pharmaceuticals
Calendar
12/06 | 08:30pmPresentation
Surperformance© rating of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 227 M
EBIT 2014 1 117 M
Net income 2014 725 M
Finance 2014 1 761 M
Yield 2014 -
Sales 2015 2 733 M
EBIT 2015 1 364 M
Net income 2015 948 M
Finance 2015 2 897 M
Yield 2015 -
PER 2014 54,59
PER 2015 40,71
EV / Sales 2014 16,5x
EV / Sales 2015 13,1x
Capitalization 38 610 M
More Financials
Latest news on ALEXION PHARMACEUTICALS, I
1d ago ALEXION PHARMACEUTICALS : Soliris secures orphan drug designation (ODD) in Japan..
1d ago ALEXION PHARMACEUTICALS : NICE Issues Final Positive Recommendation for National..
2d ago ALEXION PHARMACEUTICALS : Soliris® (eculizumab) Granted Orphan Drug Designation ..
3d ago ALEXION PHARMACEUTICALS : Soliris® (eculizumab) Granted Orphan Drug Designation ..
4d ago ALEXION PHARMACEUTICALS : Updates on Squinto's Retirement
11/18 ALEXION PHARMACEUTICALS : NASDAQ:ALXN) Investor Alert: Investigation over Potent..
11/15 ALEXION PHARMACEUTICALS : Longer-term Outcome Data from the Largest Prospective ..
11/14 ALEXION PHARMACEUTICALS : Reports Squinto's Retirement
11/12 NEUROTROPE : Appoints Warren W. Wasiewski, M.D. as Executive Vice President, Dev..
11/10 ALEXION PHARMACEUTICALS : Change in Directors or Principal Officers, Financial S..
11/10 ALEXION PHARMACEUTICALS : Pharma co-founder Squinto to retire
11/10 ALEXION PHARMACEUTICALS : Announces Planned Retirement of Stephen Squinto, Ph.D...
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF